The IL-23 inhibitor from AbbVie indicated for the treatment of adults with
active psoriatic arthritis (PsA) and for moderate to severe plaque psoriasis (Ps)
in adults who are candidates for systemic therapy or phototherapy.1

Nothing is Everything.

FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)1

Nothing less than the opportunity
to reach for their treatment goals

For your patients,
that’s everything.

ROBUST EFFICACY
IN PsA DOMAINS

SKYRIZI met its primary endpoints (ACR20 at Week 24) in 2 clinical trials. ACR50/70, complete resolution of enthesitis/dactylitis, and minimal disease activity were achieved at Week 24. Response rates observed 
up to ~3 years in PsA1-5

COMPELLING SAFETY AND TOLERABILITY RECORD

Evaluated in 24 clinical trials (4 PsA, 20 Ps). Safety profile of PsA was generally consistent with Ps (Week 16 Ps, Week 24 PsA). Up to ~9 years of safety data in Ps and 4 years in PsA. Overall rates of AEs and discontinuation observed at Week 24 and 4 years (PsA) and at Week 16 and ~9 years (Ps)1-3,6,7*

4 DOSES
A YEAR

Reliable quarterly dosing after 2 initiation doses at Week 0 and 4 (150 mg/mL injections) for PsA and Ps1

Start your appropriate patients with active PsA on SKYRIZI

LATEST HEAD-TO-HEAD Ps DATA

Learn more about the efficacy and safety data
featured in the IMMpulse trial and discover the
results of SKYRIZI vs OTEZLA (apremilast) in patients with
moderate Ps8

SKYRIZI is the #1 prescribed IL-23i for first-line PsA treatment in rheumatology.

"First-line" defined as first-time IL-23 inhibitor prescription among patients who have not been prescribed biologics or tsDMARDs in the last 3 years.

Prescriptions from rheumatologists, PAs, and NPs as of 3/2023.

Source: Integrated Symphony Health (PatientSource) and IQVIA (NSP and NPA) through proprietary method of diagnosis classification.9

ACR20 Achieved At Week 241-3

KEEPsAKE 1:

ACR20

Week 24 (primary endpoint):

57%

SKYRIZI
n=483

VS

34%

PLACEBO
n=481

KEEPsAKE 2:

ACR20

Week 24 (primary endpoint):

51%

SKYRIZI
n=224

VS

27%

PLACEBO
n=219

ACR50

Week 24 (non-ranked secondary endpoint):

33%

SKYRIZI
n=483

VS

11%

PLACEBO
n=481

ACR50

Week 24 (non-ranked secondary endpoint):

26%

SKYRIZI
n=224

VS

9%

PLACEBO
n=219

NRI-C analysis used for Week 24.

Multiplicity-controlled P≤0.001 SKYRIZI 150 mg vs placebo comparison.

Nominal P≤0.001 SKYRIZI 150 mg vs placebo comparison.

STUDY DESIGN:

KEEPsAKE 1 was a 24-week, randomized, double-blind, placebo-controlled study of 964 csDMARD-IR adult patients with active PsA.1,2

 

KEEPsAKE 2 was a 24-week, randomized, double-blind, placebo-controlled study of 443 mixed-population (~50% csDMARD-IR, ~50% bio-IR) adult patients with active PsA.1,3

ACR20/50=improvement of at least 20%/50% in tender joint count, swollen joint count, and at least 3 other core criteria; csDMARD=conventional synthetic disease-modifying antirheumatic drug; IR=inadequate response; NRI-C=non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19; PASI 90=≥90% improvement in Psoriasis Area and Severity Index; TIM=targeted immunomodulator; TNFi=tumor necrosis factor inhibitor.

PREFERRED§ COMMERCIAL AND
MEDICARE PART D COVERAGE AS A FIRST-LINE TIM THERAPY10||

SKYRIZI is covered as a first-line TIM therapy with no requirements of a prior biologic.

National commercial and Medicare Part D formulary coverage under the pharmacy benefit as of January 2024.10

NO CHARGE FOR ELIGIBLE, COMMERCIALLY INSURED PATIENTS EXPERIENCING INITIAL INSURANCE DENIAL FOR UP TO 24 MONTHS

Download or email Skyrizi Complete Enrollment
and Prescription Form

TIM=targeted immunomodulator

*Includes 4 PsA Phase 2-3 studies (including KEEPsAKE 1 and KEEPsAKE 2). Includes 20 Phase 1-4 studies in Ps encompassing 5 trials using integrated data evaluated at Week 16 (including UltlMMa-1, UltlMMa-2, IMMhance, and IMMvent), and 15 additional trials including LIMMitless.6
§SKYRIZI is on a preferred tier or otherwise has preferred status on the plan's formulary.
||Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for SKYRIZI® (risankizumab-rzaa) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for SKYRIZI at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.